Lay's chips in UAE meet 'all requirements', authority confirms amid US recall
This statement was issued in response to recent reports about a recall by the US FDA involving certain Lay's products due to undeclared milk derivatives, the authority said in a post on social media platform X.
The authority, in coordination with relevant regulatory authorities, assured consumers that all food products undergo rigorous registration and inspection processes before being sold in the UAE, ensuring they meet strict safety standards and protect public health.
The US Food and Drug Administration (FDA) recently escalated a recall of Lay's Classic Potato Chips, raising the risk level to the highest, Class I. The recall, which started on December 16, involved 6,344 bags (13 ounces each) of Lay's Classic Potato Chips distributed in Oregon and Washington.
The chips may contain undeclared milk, Frito-Lay said after being informed by a consumer.
'Those with an allergy or severe sensitivity to milk run the risk of a serious or life-threatening allergic reaction if they consume the recalled product,' the FDA said on December 16.
The chips were given the highest level classification because milk is one of the FDA's eight 'major food allergens,' meaning it is one of the products that can lead to hives, rash, cramps, dizziness, vomiting and/or diarrhoea, swollen vocal cords, difficulty breathing and even unconsciousness among those who are allergic to it.
The affected chips were sold starting November 3, 2024. It's important to note that this recall only affects the Classic Potato Chips variety, with no other products, flavours, sizes, or variety packs included.
The UAE has consistently ensured the safety of products sold in its markets. The Ministry confirmed on January 30 that Coca-Cola beverages in the country are safe for consumption and free of high levels of chlorate. This clarification came after the European bottling unit of Coca-Cola ordered a major recall of Coke, Sprite, Fanta, and other beverages on January 29 due to elevated chlorate levels.
Earlier, on January 22, the Ministry also reassured residents that pepperoni beef products withdrawn from supermarkets were safe to consume. The recall had occurred earlier in January after concerns about potential contamination with Listeria monocytogenes bacteria. MoCCAE had acted quickly on January 11 to investigate the contamination risk before allowing the products back into the market.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
2 days ago
- The National
Kuwait says 23 people dead from alcohol poisoning
Kuwait says 23 people have been killed by contaminated alcohol in the past week, with dozens more in intensive care. The Kuwaiti health ministry said 160 people had come down with methanol poisoning since Saturday. Most were Asians. Most needed urgent treatment involving mechanical breathing and kidney dialysis. Methanol is an industrial substance not meant for human consumption, but sometimes finds its way into home-made or counterfeit drinks. "The Ministry of Health warns and urges the public to avoid such behaviour to preserve lives," it said. It said there was a "continuous medical and security follow-up around the clock". An earlier ministry report on Wednesday said 21 people had suffered blindness or visual impairment due to the poisoning. India 's embassy in Kuwait said on Wednesday that about 40 Indians had been taken to hospital in recent days, some of whom had died. It did not give the reason for their sickness. The embassy said it was "following up with concerned hospitals" and the health ministry to ensure "proper treatment of Indian patients". Nine people died in Jordan in a case of mass alcohol poisoning in June, in which 47 people needed treatment. The case was referred to a criminal court.
Web Release
2 days ago
- Web Release
Mayo Clinic researchers validate blood test to diagnose Alzheimer's disease in outpatient memory clinics
Alzheimer's disease, marked by memory loss, trouble concentrating and thinking, and changes in personality and behavior, devastates patients, their families and loved ones. With new treatments available for people with early signs of Alzheimer's disease, there is a growing need for accessible and cost-effective tests to diagnose the disease sooner. In a new study, Mayo Clinic researchers confirmed the accuracy of an FDA-approved blood test that can be used at outpatient memory clinics to diagnose the disease in patients with a range of cognitive impairment. The findings are published in Alzheimer's and Dementia: The Journal of the Alzheimer's Association. Standard ways of measuring the buildup of toxic proteins in the brain that indicate Alzheimer's disease include positron emission tomography, or PET scans, and spinal taps. But these tests can be expensive and invasive. More accessible, non-invasive and cost-effective biomarkers — measurable indicators of a disease — are needed to improve diagnoses broadly in clinical settings. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' says corresponding author Gregg Day, M.D., a Mayo Clinic neurologist, dementia specialist and clinical researcher. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' The research team says their findings show promise in: Better identifying research participants with Alzheimer's disease brain changes. Screening and selecting patients with Alzheimer's disease for clinical trials. Assessing how patients respond to therapy in clinical trials. More than 500 patients receiving treatment for a range of memory issues at the outpatient Memory Disorder Clinic at Mayo Clinic in Florida participated in the study. They included patients with early- and late-onset cognitive impairment, typical and atypical Alzheimer's disease, Lewy body dementia and vascular cognitive impairment. Patients ranged from 32 to 89 years old, with the average age of symptom onset being 66. Alzheimer's disease was determined to be the underlying cause of the symptoms in 56% of the patients. The team also conducted serum tests to measure kidney disease, which can influence plasma biomarker concentrations. Mayo Clinic Laboratories tested for two proteins in blood plasma that are associated with amyloid plaque buildup, the hallmark of Alzheimer's disease: A?42/40 and p-tau217. The researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Higher plasma p-tau217 concentrations were also associated with impaired kidney function, which researchers say should be taken into account when performing the blood test. Plasma p-tau217 concentrations were positive in 267 out of 509 patients, including 233 of 246 patients (95%) with cognitive impairment attributed to Alzheimer's disease. The study was featured at the American Academy of Neurology Annual Meeting in April. In a previous study, researchers from the Mayo Clinic Laboratories team showed the utility of these blood tests compared to amyloid PET scans in research participants. Dr. Day says the next steps in this research are to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's disease who show no cognitive symptoms. The team also wants to evaluate disease-specific factors that may alter biomarker accuracy in clinical trials. Other Mayo Clinic authors include Yoav Piura, M.D., Christian Lachner, M.D., Joshua Bornhorst, Ph.D., Alicia Algeciras Schimnich, Ph.D., and Neill Graff-Radford, M.D. For a full list of authors, funding and disclosures, see the paper.
Gulf Today
4 days ago
- Gulf Today
Dubai Police arrest 3 women practising medicine without licence
The Economic Crimes Combating Department at the General Directorate of Criminal Investigation of Dubai Police, in collaboration with the Dubai Health Authority (DHA), arrested three European women for practising medicine and performing plastic surgeries without a licence in an apartment, in violation of the laws of the UAE. Dubai Police explained that they received information about suspicious activity in a residential apartment where unlicensed medical and cosmetic services were being offered. After verifying the information, a well-planned trap was set, and the apartment was raided. Three women were arrested, along with unlicensed medical tools, devices, and quantities of medications. The women were reportedly referred to the Public Prosecution for legal action. The police added that the suspects were conducting medical and plastic surgeries in unlicensed places, posing a significant risk to the health and safety of clients. Dubai Police affirmed their ongoing efforts to combat illegal medical practices and protect the health and safety of the community. They urged the public to seek services only from licensed healthcare facilities in the UAE, verify the qualifications and expertise of medical and service providers, and avoid falling for misleading offers that could endanger their lives. The police called on the public to immediately report any similar activities through the 'Police Eye' service or the 901 call centre, stressing their continued efforts to combat all forms of crime and enhance security and safety in the emirate.
